{
    "nctId": "NCT01784120",
    "briefTitle": "A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer",
    "officialTitle": "A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 48,
    "primaryOutcomeMeasure": "response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years of age or older adult women\n* Instrumentation measurable lesions with histologically confirmed advanced (recurrent or metastatic) breast cancer\n* ECOG 0-2\n* Advanced breast cancer in the past, patients who did not receive chemotherapy\n* Recurrence if adjuvant chemotherapy and adjuvant chemotherapy in the past for more than 6 months until the patient\n* life expectancy more than 3 months\n* Agree in writing before the party to participate in a clinical trial to patients\n\nExclusion Criteria:\n\n* immunohistochemical staining 3 + or FISH positive anti-HER 2 therapy patients\n* Severe infections requiring antibiotic therapy\n* Clinically significant heart disease\n* Pregnant or lactating woman\n* Uncontrolled symptoms in the central nervous system (CNS) metastases\n* Patients diagnosed with malignant tumors of other organs",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}